Bragar Eagel & Squire, P.C. Is Investigating the Officers & Directors of HeartWare International Inc. on Behalf of Stockholders
November 10 2015 - 5:30PM
Business Wire
Bragar Eagel & Squire, P.C. is investigating potential
claims on behalf of HeartWare International Inc. (NASDAQ:HTWR)
investors concerning whether the company’s officers and board of
directors violated the federal securities laws.
On October 13, 2015, HeartWare announced that the company may
not reinitiate enrollment in its MVAD heart pump clinical trials in
November 2015, as previously announced. Following the announcement
of this news, HeartWare stock plunged $8.82 per share, or 20%, to a
close at $35.21 per share on October 13, 2015.
If you purchased HeartWare securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters please contact J. Brandon Walker, Esq. by
email at investigations@bespc.com, or telephone at (212) 355-4648,
or by filling out this contact form. There is no cost or obligation
to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm
concentrating in commercial and securities litigation. For
additional information, please go to www.bespc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151110007028/en/
Bragar Eagel & Squire, P.C.J. Brandon Walker, Esq.,
212-355-4648investigations@bespc.com
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Sep 2023 to Sep 2024